Biocon Launches Liraglutide Treatments Diavorin and Vobexoryn in the Netherlands Through Pharmamedic B.V.

Biocon has introduced liraglutide, a treatment for diabetes and obesity, in the Netherlands. The products are being marketed under the brand names Diavorin and Vobexoryn through Pharmamedic B.V., a local pharmaceutical distributor. This launch marks Biocon’s latest effort to expand its portfolio of therapeutic solutions in Europe.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist commonly used to manage blood sugar levels in individuals with type 2 diabetes and to support weight management in patients with obesity. By partnering with Pharmamedic B.V., Biocon aims to make these treatments more accessible within the Dutch healthcare system. The company has not disclosed further details regarding pricing or distribution strategies at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 15, 2025

Author

GOAI